Why is NKTR down?
Down 19% over the five sessions to Nov 20 while the S&P 500 fell 9%.
- Nektar Therapeutics fell 19% in those sessions while biotech stocks fell a median 9%:
−2Long-term trend
Down 19% over the five sessions to Nov 20 while the S&P 500 fell 9%.
−2Long-term trend
NKTR's Quality Score rose 1 point on Fri, Nov 20, to -10. More shares traded than usual.
Follow NKTR's trial news. Pro members can get an alert when Nektar Therapeutics files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Since its Dec 2021 high | Down 86% |
| Latest filing | 10-Q, Nov 13 |
After its last 4 reports it closed -0.4% on average, higher 2 of 4 times.
About 9 quarters
CEO Howard W. Robin sold 429 shares on Nov 17. 11 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
NKTR is #267 of 273 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 267 |
Expected to report Thu Mar 18, after the close (in 117 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $9.4M, 20% less than a year ago; a loss of $1.63 a share, from $1.87.
“R&D expense increased primarily due to activities to support the Phase 3 ZENITH AD program in atopic dermatitis and the Phase 3 ZENITH AA program in alopecia areata, as well as manufacturing activities”
NKTR's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
Sales fell 18% a year over 5 years, fiscal 2020 to 2025.
Its share count grew 5.8% a year over 5 years.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 12, 2026 | -1.2% | +0.1% | -12.6% |
| Aug 13, 2026 | -2.5% | -3.8% | -1.8% |
| May 7, 2026 | +1.9% | -1.8% | -10.8% |
Sales grew in two of the last seven years, to $55.2M in 2025. It made a profit in one of the eight years.
RSI 23.4, MACD below signal, below both averages. Not scored.
2 insiders sold $66K across 4 filings in the last 6 months. No open-market buys on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: NKTR is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
“Competition in the pharmaceutical and biotechnology industry is intense and characterized by aggressive research and development and rapidly-evolving science, technology, and standards of medical care throughout the world.”
NKTR scores -10 today, which Breakaway calls Poor. It is #267 of 273 in Biotech by Quality Score, with 1 of 14 chart checks firing. Down 19% over the five sessions to Nov 20 while the S&P 500 fell 9%. Cash lasts about 9 quarters at its spending (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
NKTR scores -10 today, which Breakaway calls Poor (below zero). That is #267 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind NKTR's -10.
2 insiders sold $66K across 4 filings in the last 6 months. No open-market buys on record. The newest is Howard W. Robin, President & CEO, who sold $15K on Nov 17. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.